Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Recursion Pharmaceuticals, Inc.

NASDAQ: RXRX · Life Sciences · 7 alerts · CIK 1601830

Share price
$2.90Close, Nov 16
Market cap
$1.81B
Shares outstanding
622.76MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Recursion Pharmaceuticals, Inc. filings on SEC EDGAR ↗

8:47 AM ET 8-K
Capital Raise

Recursion Pharmaceuticals Capital Raise of $200M

Recursion Pharmaceuticals entered into an underwriting agreement to raise approximately $200 million through a public offering of 61,540,000 shares of Class A common stock at $3.25 per share. The company also announced that Sanofi exercised an option for a first-in-class immunology development candidate under their existing collaboration, triggering a $10 million milestone payment. Proceeds from the equity raise are expected to extend the company's cash runway into 2029.

Value
$200M
Counterparty
Leerink Partners LLC
9:05 AM ET 8-K
Licensing Deal

Recursion Pharmaceuticals Licensing Deal with Tempus AI, Inc. Worth $12M

Recursion Pharmaceuticals granted Tempus AI a non-exclusive license to its TxFM RNA sequencing model for use in oncology in exchange for a $12 million license fee. Simultaneously, the parties amended an existing master agreement to extend its term to six years and restructure annual license fees, while Recursion gained access to additional de-identified pathology records.

Value
$12M
Counterparty
Tempus AI, Inc.
Term
2 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.